Literature DB >> 12555872

Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review.

N P Rowell1, F V Gleeson.   

Abstract

OBJECTIVE: To conduct a systematic review to determine the relative effectiveness of treatments currently employed in the management of superior vena caval obstruction (SVCO). SEARCH STRATEGY: Electronic searching of the Cochrane Clinical Trials Register, Medline and Embase with identification of further studies from references cited in trials identified by electronic searching. SELECTION CRITERIA: Both randomized and non-randomized controlled trials in which patients with carcinoma of the bronchus and SVCO had been treated with any combination of steroids, chemotherapy, radiotherapy or insertion of an expandable metal stent. DATA COLLECTION AND ANALYSIS: There were three randomized and 98 non-randomized studies of which two and 44 respectively met the inclusion criteria. MAIN
RESULTS: Superior vena caval obstruction was present at diagnosis in 10.0% of patients with small cell lung cancer (SCLC) and 1.7% of patients with non-small cell lung cancer (NSCLC). In one small randomized trial in SCLC, the rate of SVCO relapse was not significantly reduced by giving radiotherapy on completion of chemotherapy. In another, in NSCLC, the addition of induction chemotherapy to a course of synchronous chemo-radiotherapy did not provide greater relief of SVCO. In SCLC chemotherapy and/or radiotherapy relieved SVCO in 77%; 17% of those treated had a recurrence of SVCO. In NSCLC, 60% had relief of SVCO following chemotherapy and/or radiotherapy; 19% of those treated had a recurrence of SVCO. Insertion of an SVC stent relieved SVCO in 95%; 11% of those treated had further SVCO but recanalization was possible in the majority resulting in a long-term patency rate of 92%. Morbidity following stent insertion was greater if thrombolytics were administered. REVIEWERS'
CONCLUSIONS: Chemotherapy and radiotherapy are effective in relieving SVCO in a proportion of patients whilst stent insertion may provide relief in a higher proportion and more rapidly. The effectiveness of steroids and the optimal timing of stent insertion (whether at diagnosis or following failure of other modalities) remain uncertain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12555872     DOI: 10.1053/clon.2002.0095

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  30 in total

Review 1.  [Compression syndromes].

Authors:  J Wierecky; C Bokemeyer
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 2.  Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment? CME.

Authors:  Jose Alvarez-Cardona; Joshua Mitchell; Daniel Lenihan
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 3.  Endovascular stenting to treat obstruction of the superior vena cava.

Authors:  Anthony F Watkinson; Tow Non Yeow; Clementine Fraser
Journal:  BMJ       Date:  2008-06-21

4.  Pulseless Electrical Activity Arrest after SVC Dilation.

Authors:  Brian Funaki; Taral Doshi
Journal:  Semin Intervent Radiol       Date:  2007-12       Impact factor: 1.513

5.  Stent insertion for malignant superior vena cava syndrome: effectiveness and long-term outcome.

Authors:  Su Niu; Yuan-Shun Xu; Long Cheng; Chi Cao
Journal:  Radiol Med       Date:  2017-04-20       Impact factor: 3.469

6.  Superior vena cava syndrome as a clinical manifestation of recurrent cervical cancer.

Authors:  Khalid Jumean; Amer Hawatmeh; Ahmad Arqoub; Hamid Shaaban
Journal:  Lung India       Date:  2016 Mar-Apr

7.  Successful treatment of malignant superior vena cava syndrome using a stent-graft.

Authors:  Dong Il Gwon; Sang Hyun Paik
Journal:  Korean J Radiol       Date:  2012-03-07       Impact factor: 3.500

8.  Stereotactic body radiotherapy for superior vena cava syndrome.

Authors:  Joshua T McKenzie; Emory McTyre; Dan Kunaprayoon; Kevin P Redmond
Journal:  Rep Pract Oncol Radiother       Date:  2013-01-16

9.  Endovascular stent-based revascularization of malignant superior vena cava syndrome with concomitant implantation of a port device using a dual venous approach.

Authors:  Susanne Anton; T Oechtering; E Stahlberg; F Jacob; M Kleemann; J Barkhausen; J P Goltz
Journal:  Support Care Cancer       Date:  2017-12-22       Impact factor: 3.603

10.  Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases.

Authors:  Karin Hohloch; Nick Bertram; Lorenz Trümper; Tim Beissbarth; Frank Griesinger
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.